These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 19823051)

  • 1. Efficacy of human papillomavirus vaccines: a systematic quantitative review.
    Medeiros LR; Rosa DD; da Rosa MI; Bozzetti MC; Zanini RR
    Int J Gynecol Cancer; 2009 Oct; 19(7):1166-76. PubMed ID: 19823051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review.
    Gonçalves AK; Cobucci RN; Rodrigues HM; de Melo AG; Giraldo PC
    Braz J Infect Dis; 2014; 18(6):651-9. PubMed ID: 24780368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.
    Frederick PJ; Huh WK;
    Expert Rev Anticancer Ther; 2008 May; 8(5):701-5. PubMed ID: 18471043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT; Castellsagué X; Villa LL; Hildesheim A
    Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
    Arbyn M; Xu L
    Expert Rev Vaccines; 2018 Dec; 17(12):1085-1091. PubMed ID: 30495978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus.
    Mavundza EJ; Wiyeh AB; Mahasha PW; Halle-Ekane G; Wiysonge CS
    Hum Vaccin Immunother; 2020; 16(2):426-435. PubMed ID: 31448991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.
    Miltz A; Price H; Shahmanesh M; Copas A; Gilson R
    PLoS One; 2014; 9(3):e90348. PubMed ID: 24595046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus and vaccination in cervical cancer.
    Wang KL
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):352-62. PubMed ID: 18182340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
    Harper DM; Franco EL; Wheeler CM; Moscicki AB; Romanowski B; Roteli-Martins CM; Jenkins D; Schuind A; Costa Clemens SA; Dubin G;
    Lancet; 2006 Apr; 367(9518):1247-55. PubMed ID: 16631880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group
    N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
    Yoshikawa H; Ebihara K; Tanaka Y; Noda K
    Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
    McIntosh J; Sturpe DA; Khanna N
    J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diseases caused by human papilloma viruses].
    Zollner U; Schwarz TF
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.